ClinConnect ClinConnect Logo
Search / Trial NCT05578885

Duration of Analgesia in Bier Block for Patients Undergoing Hand Surgery

Launched by MICHAEL BISHAY SHEHATA KEROLES · Oct 11, 2022

Trial Information

Current as of May 20, 2025

Not yet recruiting

Keywords

Dexamethasone Intravenous Regional Anesthesia Fentanyl Lidocaine

ClinConnect Summary

This clinical trial is looking at a specific way to manage pain called a Bier block, which is a type of regional anesthesia used during hand surgeries. The goal is to see how long this method can effectively relieve pain for patients undergoing operations on their hands or arms. This technique is particularly useful for patients who cannot have general anesthesia due to health concerns.

To be eligible for this trial, participants should be between the ages of 18 and 65 and classified as ASA Grade 1 or 2, meaning they are generally healthy or have mild health issues. Unfortunately, those with more serious health conditions, such as severe heart or lung problems, certain neurological disorders, or those who have had issues with blood circulation, won't be able to participate. If you join the study, you can expect to receive the Bier block anesthesia during your surgery and be monitored for how well it works for pain relief. The trial is not yet recruiting, so there's still time to learn more about it before making a decision.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • ASA Grade 1 \& 2
  • Exclusion Criteria:
  • Patient refusal ASA Grade 3 \& 4 patients SEVERLY HYPOVOLEMIC STATE History of neurological. Reynauds disease, scleroderma, sickle cell anemia, myasthenia gravis, decompensated cardiac disease, diabetes mellitus, peptic ulcer, gastritis, and those with liver or renal insufficiency were excluded

About Michael Bishay Shehata Keroles

Michael Bishay Shehata Keroles is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on ethical standards and regulatory compliance, he leads innovative studies that explore new therapeutic interventions across various medical fields. His expertise in trial design and execution, combined with a strong emphasis on patient safety and data integrity, positions him as a key contributor to the scientific community. Through collaboration with research institutions and healthcare professionals, Michael aims to foster breakthroughs that enhance the understanding and treatment of complex health issues.

Locations

Assiut, , Egypt

Patients applied

0 patients applied

Trial Officials

Michael Shehata, Resident

Principal Investigator

Assiut University

Eman Ismail, Professor

Study Director

Assiut University

Alaa Atia, Professor

Study Director

Assiut University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials